Biolife Solutions (BLFS) executive compensation, 2025 proxy

Roderick de Greef, Chief Executive Officer and Chairman of the Board, was paid $7M in 2024, up 33% from $5.3M the year before. The CEO-to-median-employee pay ratio was 58:1, on median employee pay of $122,390.

Filed
July 8, 2025
Annual meeting
August 20, 2025
Pay year
2024
Named executives
6
CEO total pay
$7M+33% vs prior year
CEO to median employee
58:1median $122,390
CEO pay in equity
79%$5.6M in awards
Prior say-on-pay support
82%of votes cast
2024 revenue
$82.3M8% year-over-year increase
Adjusted EBITDA
$15.6M19% of revenue
CEO CAP
$12,358,698Compensation actually paid
Total NEO pay
$14,329,428Six NEOs in 2024

How Greef was paid

$7M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Stock awards79%Non-equity incentive9%All other compensation1%

Named executive officers

ExecutiveTotal
Roderick de GreefChief Executive Officer and Chairman of the Board$7,046,205
Aby J. MathewExecutive Vice President and Chief Scientific Officer$1,733,494
Troy WichtermanChief Financial Officer$2,554,007
Todd BerardChief Commercial Officer$1,127,495
Garrie RichardsonFormer Chief Revenue Officer$1,387,288
Karen FosterChief Quality and Operations Officer$1,515,139

What changed and why

  • $7.05M$7.05M CEO total compensation increased from $5.32M in 2023.
  • $5.57M$5.57M CEO stock awards included performance-based and market-based restricted stock.
  • 200%200% Maximum vesting applied to performance-based and market-based restricted stock awards.
  • $655K$655,116 CEO non-equity incentive compensation reflected achievement of Company Objectives.
  • $418K$417,976 in other compensation represented severance paid to former Chief Revenue Officer Garrie Richardson.
  • 82.4%82.4% of votes supported the prior year’s say-on-pay proposal.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.